Medinol Group is a MedTech Hub focused on the development of innovative medical technologies of implantable medical devices.

Stenting and Catheterization

Structural Heart

Implantable Microsensors


Leveraging superior in-house R&D, clinical and regulatory capabilities, robust patent portfolio and legacy of innovation the Medinol Group continuously redefines medical device development with medical innovations and technological advancements.

Clinical Program



May 5, 2020

Medinol Completes Enrollment of EluNIR-HBR Study

Apr 4, 2020

Medinol Enrolls a First-in-Human Study of ChampioNIR® SFA Stent System

Jan 1, 2018

Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ ...

Nov 11, 2017

Cordis Announce FDA Approval of the Innovative EluNIR™ Drug-Eluting Stent ...

Oct 10, 2017

Medinol Ltd. Receives CE Mark for the EluNIR™ Ridaforolimus-Eluting ...

Dec 12, 2016

Medinol announces excellent clinical results for EluNIR, a novel Drug ...

Nov 11, 2016

Medinol Receives Approval from The Japanese PMDA to Begin Clinical Study on ...

Oct 10, 2016

Study Finds Medinol’s Ridaforolimus-Eluting Stent Is Non-Inferior to ...